Tenon Medical (NASDAQ:TNON) Releases Quarterly Earnings Results, Misses Expectations By $3.95 EPS

Tenon Medical (NASDAQ:TNON) posted its earnings results on Thursday. The company reported ($12.35) EPS for the quarter, missing analysts’ consensus estimates of ($8.40) by ($3.95), FiscalAI reports. Tenon Medical had a negative return on equity of 1,636.44% and a negative net margin of 257.85%.The firm had revenue of $1.28 million for the quarter, compared to analyst estimates of $1.54 million.

Here are the key takeaways from Tenon Medical’s conference call:

• Revenue and gross profit surged: Second-quarter revenue rose 127% year over year to $1.3 million, while gross profit increased 232% to $0.8 million. Gross margin expanded to 64% from 43%, aided by higher procedure volumes and improved fixed-cost absorption.
• Physician and distributor training events increased 98% in the first half versus the second half of 2025, supported by the new Tampa training center. Management said the facility contributed to a record monthly case volume in July and a strong start to the third quarter.
• FDA 510(k) clearance for the updated Catamaran system is expected to reduce per-procedure costs through reusable instruments and improve margins beginning in the third quarter. The company is also preparing enhancements to Symmetry Plus and additional products for potential regulatory filing and launch.
• Tenon raised $4.2 million in gross proceeds through a July 1 public offering, providing additional funding for commercial expansion, clinical research, product development, and partial repayment of convertible notes.
• The company remains loss-making, with a second-quarter net loss of $4.1 million and $1.7 million in cash at quarter-end. Operating expenses increased, and the six-month operating loss was essentially unchanged year over year despite revenue more than doubling; additional non-cash interest expense also increased the net loss.

Tenon Medical Stock Down 13.4%

Shares of NASDAQ:TNON traded down $0.80 on Friday, reaching $5.16. The company had a trading volume of 34,054 shares, compared to its average volume of 62,164. The stock has a market capitalization of $1.75 million, a P/E ratio of -0.12 and a beta of 1.39. The stock has a 50-day moving average price of $10.95 and a 200 day moving average price of $21.31. Tenon Medical has a twelve month low of $4.38 and a twelve month high of $54.95.

Institutional Investors Weigh In On Tenon Medical

Several hedge funds have recently made changes to their positions in TNON. Jane Street Group LLC acquired a new stake in shares of Tenon Medical during the 1st quarter valued at about $29,000. Geode Capital Management LLC raised its position in Tenon Medical by 34.6% in the 4th quarter. Geode Capital Management LLC now owns 66,640 shares of the company’s stock worth $63,000 after purchasing an additional 17,137 shares during the last quarter. Finally, DRW Securities LLC acquired a new position in shares of Tenon Medical during the fourth quarter valued at $98,000. Institutional investors own 22.74% of the company’s stock.

Analyst Ratings Changes

Several analysts have weighed in on TNON shares. Weiss Ratings reiterated a “sell (e+)” rating on shares of Tenon Medical in a research note on Friday, July 17th. Alliance Global Partners reissued a “buy” rating on shares of Tenon Medical in a research note on Wednesday, May 13th. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold”.

About Tenon Medical

Tenon Medical, Inc is a development-stage medical device company focused on the research, development and commercialization of next-generation surgical biologic adhesives and sealants. The company’s proprietary platform is designed to create tissue-compatible adhesives that can serve as alternatives or complements to traditional sutures and staples, with the goal of improving surgical efficiency, reducing postoperative complications and enhancing patient outcomes.

Tenon Medical’s product pipeline centers on protein-based polymer formulations that cross-link in situ to form a flexible, yet durable, bond with native tissue.